The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...
February is heart month, a time to think about the health of your and your loved ones’ arteries. If arteries get stressed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback